Hana Pharm Co Ltd (293480) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hana Pharm Co Ltd stock KRW 9,552, price KRW 8,110, upside +17.8%, quality 52 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 8,070 KRW – 19,727 KRW · fair‑value band 6,686 KRW – 11,883 KRW · the 8,110 KRW price screens below the 9,552 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Hana Pharm Co in your weekly email
Every Wednesday you see whether Hana Pharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally.
Show moreShow less
It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs.
The company was founded in 1996 and is headquartered in Seoul, South Korea.
Stock analysis
Hana Pharm Co Ltd (293480) currently trades at 8,110 KRW, while our model-based Fair Value estimate is 9,552 KRW, implying the stock looks roughly 15% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 15,833 KRW per share, and 11 of the 16 models we run sit above the 8,110 KRW price.
Bear case: the Earnings-Based group reads lowest at 5,861 KRW, and 5 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 6,686 KRW (bear) to 11,883 KRW (bull), the price of 8,110 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hana Pharm Co Ltd reported revenue of 240B KRW in FY2025 versus 196B KRW in FY2021, a compound +5.1%/yr. Reported net income was 8.8B KRW in FY2025, compounding −25.2%/yr from FY2021.
Key figures
Market cap 140B KRW (≈ $104M) Micro · P/E ratio 5.9 · P/S ratio 0.22 · EPS (TTM) 1,371 KRW · Dividend yield 3.2% · Net margin 3.7% · Return on equity 35.5% · Return on assets (EBIT) 8.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 18%, 293480 screens cheaper than that median.
Fair Value models
Bear6,686 KRWFair Value 9,552 KRWBull11,883 KRW
Price 8,110 KRW · Upside +17.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (953.03 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.1%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 11%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+17.8% · Above median
Profitability
Return on equity (12 months)35.5% · Top 25%
Return on assets2.1% · Below median
Net margin (12 months)17.4% · Top 25%
Operating margin (12 months)22.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Dividend yield (12 months)3.2% · Above median
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hana Pharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/293480
Frequently asked questions
Is Hana Pharm Co Ltd (293480) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 9,552 KRW versus a price of 8,110 KRW, about +18% upside (undervalued).
What is the fair value of 293480?
Our model-based fair value for Hana Pharm Co Ltd is 9,552 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 8,110 KRW.
What is the quality score of 293480?
Hana Pharm Co Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hana Pharm Co Ltd (293480)?
Our model-based price target is the fair value of 9,552 KRW (as of Nov 7, 2026) from 16 valuation models. Cautious scenario 6,686 KRW, optimistic scenario 11,883 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Hana Pharm Co Ltd stock forecast for 2026?
Our models put fair value at 9,552 KRW, about +18% upside versus a price of 8,110 KRW (undervalued). Cautious scenario 6,686 KRW, optimistic scenario 11,883 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hana Pharm Co Ltd (293480)?
Hana Pharm Co Ltd reported trailing-twelve-month revenue of about 139B KRW (latest available figure, as of Nov 7, 2026).
Does Hana Pharm Co Ltd pay a dividend?
Hana Pharm Co Ltd currently shows a dividend yield of 3.21% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Hana Pharm Co Ltd (293480) and when is the ex-dividend date?
Hana Pharm Co Ltd pays a dividend of 260.00 KRW per share a year, a dividend yield of 3.2%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 19.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Hana Pharm Co Ltd (293480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hana Pharm Co Ltd it is 9,552 KRW per share (as of Nov 7, 2026), against a price of 8,110 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hana Pharm Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 293480 trades below its calculated fair value: price 8,110 KRW, fair value 9,552 KRW, a gap of about +18% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 293480?
No. The price is what the market pays today (8,110 KRW); the fair value is what the company's own numbers justify (9,552 KRW). For Hana Pharm Co Ltd the two are 1,442 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hana Pharm Co Ltd worth?
The market values Hana Pharm Co Ltd at about 140B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 8,110 KRW; our models calculate a fair value of 9,552 KRW per share.
What do the bullish and bearish scenarios say about 293480?
Our models span a range for Hana Pharm Co Ltd: cautious scenario 6,686 KRW, base 9,552 KRW, optimistic 11,883 KRW per share (as of Nov 7, 2026, price 8,110 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 293480?
Hana Pharm Co Ltd trades at a price-to-earnings ratio of 5.9 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9,552 KRW is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 12.4. Other multiples: P/B 0.5, P/S 1.0, EV/EBITDA 4.3.
How solid is the balance sheet of Hana Pharm Co Ltd (293480)?
Balance-sheet figures for Hana Pharm Co Ltd (as of Nov 7, 2026): return on equity 35.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 293480 from its 52-week high?
Hana Pharm Co Ltd trades at 8,110 KRW, about 30% below its 52-week high of 11,560 KRW and at the low of 8,070 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 9,552 KRW is for.
Which stocks are comparable to Hana Pharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hana Pharm Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price 8,110 KRW, calculated fair value 9,552 KRW (+18%), Quality Score 52/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 293480 calculated?
We run Hana Pharm Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 9,552 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hana Pharm Co Ltd currently trades 15% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hana Pharm Co Ltd (293480)?
The closing price on Nov 6, 2026 was 8,110 KRW. Our model-based fair value is 9,552 KRW, about +18% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hana Pharm Co Ltd right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Hana Pharm Co Ltd
How large is the market capitalisation of Hana Pharm Co Ltd (293480)?
The market capitalisation of Hana Pharm Co Ltd is 140B KRW (≈ $104M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hana Pharm Co Ltd (293480)?
The price-to-sales ratio of Hana Pharm Co Ltd is 0.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hana Pharm Co Ltd (293480)?
Earnings per share at Hana Pharm Co Ltd are 1,371 KRW (price ÷ EPS = P/E 5.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hana Pharm Co Ltd (293480)?
The dividend yield of Hana Pharm Co Ltd is 3.2% (payout 19.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hana Pharm Co Ltd (293480)?
The net margin of Hana Pharm Co Ltd is 3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hana Pharm Co Ltd (293480)?
The return on equity (ROE) of Hana Pharm Co Ltd is 35.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hana Pharm Co Ltd (293480)?
On an EBIT basis the return on assets of Hana Pharm Co Ltd is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hana Pharm Co Ltd (293480)?
The operating margin of Hana Pharm Co Ltd is 22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Hana Pharm Co Ltd (293480) generate?
The free cash flow of Hana Pharm Co Ltd is −22.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hana Pharm Co Ltd (293480) carry?
The net debt of Hana Pharm Co Ltd is 46.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hana Pharm Co Ltd in the live analysis
One click puts Hana Pharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026